These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19528243)

  • 21. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
    Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
    Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
    Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L
    Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of AMPK activation and combined treatment with AMPK activators and somatostatin on hormone secretion and cell growth in cultured GH-secreting pituitary tumor cells.
    Tulipano G; Faggi L; Losa M; Mortini P; Spinello M; Sibilia V; Pagani F; Cocchi D; Giustina A
    Mol Cell Endocrinol; 2013 Jan; 365(2):197-206. PubMed ID: 23116772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma.
    Di Leo A; Bajetta E; Ferrari L; Biganzoli L; Mariani L; Carnaghi C; Camerini E; Buzzoni R; Ruiz JM
    Cancer; 1996 Jul; 78(1):35-42. PubMed ID: 8646723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
    Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
    Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
    Petersen C; Petersen S; Milas L; Lang FF; Tofilon PJ
    Clin Cancer Res; 2000 Jun; 6(6):2513-20. PubMed ID: 10873107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
    Palazzo M; Lombard-Bohas C; Cadiot G; Matysiak-Budnik T; Rebours V; Vullierme MP; Couvelard A; Hentic O; Ruszniewski P
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):232-8. PubMed ID: 23108416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
    Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
    J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors.
    Fotouhi O; Kjellin H; Larsson C; Hashemi J; Barriuso J; Juhlin CC; Lu M; Höög A; Pastrián LG; Lamarca A; Soto VH; Zedenius J; Mendiola M; Lehtiö J; Kjellman M
    J Clin Endocrinol Metab; 2016 Oct; 101(10):3616-3627. PubMed ID: 27459532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioprotective effects of Antrodia cinnamomea are enhanced on immune cells and inhibited on cancer cells.
    Cheng PC; Huang CC; Chiang PF; Lin CN; Li LL; Lee TW; Lin B; Chen IC; Chang KW; Fan CK; Luo TY
    Int J Radiat Biol; 2014 Oct; 90(10):841-52. PubMed ID: 24708166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.
    Cendros JM; Peraire C; Trocóniz IF; Obach R
    Metabolism; 2005 Oct; 54(10):1276-81. PubMed ID: 16154424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P; Morange-Ramos I; Cogne M; Jaquet P
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The aging suppressor klotho: a potential regulator of growth hormone secretion.
    Shahmoon S; Rubinfeld H; Wolf I; Cohen ZR; Hadani M; Shimon I; Rubinek T
    Am J Physiol Endocrinol Metab; 2014 Aug; 307(3):E326-34. PubMed ID: 24939736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma.
    Schütze C; Dörfler A; Eicheler W; Zips D; Hering S; Solca F; Baumann M; Krause M
    Strahlenther Onkol; 2007 May; 183(5):256-64. PubMed ID: 17497097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
    Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
    J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lanreotide for the treatment of acromegaly.
    Castinetti F; Saveanu A; Morange I; Brue T
    Adv Ther; 2009 Jun; 26(6):600-12. PubMed ID: 19533047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiopharmacokinetic and dosimetric parameters of 188Re-lanreotide in athymic mice with induced human cancer tumors.
    Molina-Trinidad EM; de Murphy CA; Ferro-Flores G; Murphy-Stack E; Jung-Cook H
    Int J Pharm; 2006 Mar; 310(1-2):125-30. PubMed ID: 16423478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells.
    An J; Pei X; Zang Z; Zhou Z; Hu J; Zheng X; Zhang Y; He J; Duan L; Shen R; Zhang W; Zhu F; Li S; Yang H
    Oncotarget; 2017 Jun; 8(23):37538-37549. PubMed ID: 28380462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.